Related to Phase III Data Shows Novartis’ Canakinumab Enables SJIA Patients to Remain Symptom Free

• Japan Approves Novartis’ MS Drug Gilenya and CAPS Treatment Ilaris
  
• New England Research Institutes Scores $45M to Support the Pediatric Heart Network
  
• BGI and The Children's Hospital of Philadelphia Set Up Genome Center to Target Pediatric Diseases
  
• EC Clears Novartis’ Blood Pressure Therapy
  
• Trial Shows Dangers of Combining Novartis’ Aliskiren with ACE-Inhibitor or ARB
  
• ViroPharma Pays Meritage Initial $7.5M for Option to Acquire Firm for EoE Drug
  
• Novartis Plans $450M Cost Cuts to Shoulder Diovan Patent Loss, Aliskiren Safety Concerns
  
• Chinese Regulator Clears Novartis’ Wet AMD Drug Lucentis
  
• FDA Approves Label Change Recommending Three Years of Novartis' Glivec After GIST Surgery
  
• Novartis Pays Enanta $34M Up Front for Worldwide Rights to HCV NS5A Inhibitors
  
• EC Approves Three-Year Treatment Label Update for Novartis’ Glivec
  
• India's Top Court Set to Hear Novartis Challenge to Patent Law
  
• Is Novartis Looking to Turkey for Emerging Markets HQ?
  
• Vectura, Novartis' COPD Therapy Succeeds in Fourth Phase III Study
  
• EC Approves Novartis’ Cushing Disease Therapy Signifor
  
• Novartis’ Afinitor Gets FDA Okay for Treating Renal Angiomyolipoma Associated with TSC
  
• Novartis to Buy Dermatology Generics Firm Fougera for $1.525B Cash
  
• Novartis Reports Positive Phase III Data for Acromegaly Therapy
  
• Novartis Pays Genmab $2M to Tap into Bispecific Antibody Technology
  
• Mutations IDed in Pediatric Brain Cancer